Novartis Aktie

93,33 EUR -0,23 EUR -0,25 %

17:02:21

L&S

86,94 CHF -0,10 CHF -0,11 %

17:19:59

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.182,80 Mrd. EUR

KGV13,21Div. Rendite3,89%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

06.09.23GlobeNewswireNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Com

05.09.23GlobeNewswireSandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023

05.09.23GlobeNewswireSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements

28.08.23GlobeNewswireNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

28.08.23GlobeNewswireSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

25.08.23GlobeNewswireSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

18.08.23GlobeNewswireNovartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off

18.08.23GlobeNewswireNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote

15.08.23GlobeNewswireSandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept

11.08.23GlobeNewswireNovartis Completes Acquisition of Chinook Therapeutics

09.08.23GlobeNewswireNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria

24.07.23GlobeNewswireSandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab

20.07.23GlobeNewswireSandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline

18.07.23GlobeNewswireNovartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz[1],[2

18.07.23GlobeNewswireNovartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off[1],[2]

07.07.23GlobeNewswireNovartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook

01.07.23GlobeNewswireSandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space

30.06.23GlobeNewswireNovartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy

15.06.23GlobeNewswireSandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines

12.06.23GlobeNewswireNovartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)

08.06.23PR NewswireKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

08.06.23GlobeNewswireSandoz presents compelling investment proposition as standalone company at Capital Markets Day

02.06.23GlobeNewswireNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

01.06.23GlobeNewswireSandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company

25.05.23GlobeNewswireSandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA

15.05.23GlobeNewswireNew Sandoz Board of Directors appointed

11.05.23GlobeNewswireNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting

09.05.23GlobeNewswireSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars

04.05.23GlobeNewswireSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines

26.04.23GlobeNewswireNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

26.04.23GlobeNewswireNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO

26.04.23GlobeNewswireNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

25.04.23GlobeNewswireNovartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose

25.04.23GlobeNewswireNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance

20.04.23GlobeNewswireNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

03.04.23GlobeNewswireSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

31.03.23GlobeNewswireNovartis Entresto receives positive CHMP opinion for pediatric heart failure

27.03.23GlobeNewswireNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

21.03.23GlobeNewswireSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

20.03.23GlobeNewswireNovartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.